(2)
MUMBAI, India, Dec. 15, 2020 /PRNewswire/ Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan s 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. This accolade is a testament to the success of the company s flagship liquid biopsy, the Guardant360 test, which oncologists are using to guide treatment decisions for advanced stage cancer patients.
Photo - https://mma.prnewswire.com/media/1384995/Award Guardant Health.jpg
Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered globally as the standard of care. Available in 41 countries across AMEA, the company s Guardant360 test provides quick and accurate comprehensive genomic profiling (CGP) information from a simple blood draw in seven days upon sample receipt in the laboratory.